Tremelimumab/Durvalumab Plus Chemo Improves Survival in Metastatic NSCLC
January 8th 2024Adding a limited course of tremelimumab to frontline durvalumab and chemotherapy may provide patients with previously untreated metastatic non-small cell lung cancer a sustained overall survival benefit compared with chemotherapy alone.